{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:40:26Z","timestamp":1787496026248,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04809-1","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T14:32:55Z","timestamp":1759933975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti\u2013PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results"],"prefix":"10.1007","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4246-9344","authenticated-orcid":false,"given":"Jayesh","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Deva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"O\u2019Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meili","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Meniawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Voskoboynik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diwakar","family":"Davar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiangjiin","family":"Leaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahmina","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Giovinazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"issue":"2","key":"4809_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/antib9020017","volume":"9","author":"J Golay","year":"2020","unstructured":"Golay J, Andrea AE (2020) Combined anti-cancer strategies based on anti-checkpoint inhibitor antibodies. Antibodies (Basel) 9(2):17. https:\/\/doi.org\/10.3390\/antib9020017","journal-title":"Antibodies (Basel)"},{"key":"4809_CR2","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert C (2020) A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun 11:3801. https:\/\/doi.org\/10.1038\/s41467-020-17670-y","journal-title":"NatCommun"},{"key":"4809_CR3","doi-asserted-by":"publisher","first-page":"e000573","DOI":"10.1136\/esmoopen-2019-000573","volume":"5","author":"C Alves Costa Silva","year":"2020","unstructured":"Alves Costa Silva C, Facchinetti F, Routy B, Derosa L (2020) New pathways in immune stimulation: targeting OX40. ESMO Open 5:e000573. https:\/\/doi.org\/10.1136\/esmoopen-2019-000573","journal-title":"ESMO Open"},{"key":"4809_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2019.12.010","volume":"13","author":"L Barrueto","year":"2020","unstructured":"Barrueto L, Caminero F, Cash L, Makris C, Lamichhane P, Deshmukh RR (2020) Resistance to checkpoint inhibition in cancer immunotherapy. Transl Oncol 13:100738. https:\/\/doi.org\/10.1016\/j.tranon.2019.12.010","journal-title":"Transl Oncol"},{"key":"4809_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","volume":"11","author":"JA Marin-Acevedo","year":"2018","unstructured":"Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y (2018) Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol 11:39. https:\/\/doi.org\/10.1186\/s13045-018-0582-8","journal-title":"J Hematol Oncol"},{"key":"4809_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41392-022-00895-2","volume":"7","author":"R Sun","year":"2022","unstructured":"Sun R, Zhang PP, Weng XQ, Gao XD, Huang CX, Wang L, Hu XX, Xu PP, Cheng L, Jiang L, Fu D, Qu B, Zhao Y, Feng Y, Dou HJ, Zheng Z, Zhao WL (2022) Therapeutic targeting miR130b counteracts diffuse large B-cell lymphoma progression via OX40\/OX40L-mediated interaction with Th17 cells. Signal Transduct Target Ther 7:80. https:\/\/doi.org\/10.1038\/s41392-022-00895-2","journal-title":"Signal Transduct Target Ther"},{"key":"4809_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.imlet.2006.04.001","volume":"106","author":"T Fujita","year":"2006","unstructured":"Fujita T, Ukyo N, Hori T, Uchiyama T (2006) Functional characterization of OX40 expressed on human CD8\u2009+\u2009T cells. Immunol Lett 106:27\u201333. https:\/\/doi.org\/10.1016\/j.imlet.2006.04.001","journal-title":"Immunol Lett"},{"key":"4809_CR8","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1158\/1078-0432.CCR-15-2614","volume":"22","author":"C Lai","year":"2016","unstructured":"Lai C, August S, Albibas A, Behar R, Cho SY, Polak ME, Theaker J, MacLeod AS, French RR, Glennie MJ, Al-Shamkhani A, Healy E (2016) OX40\u2009+\u2009regulatory T cells in cutaneous squamous cell carcinoma suppress effector T-cell responses and associate with metastatic potential. Clin Cancer Res 22:4236\u20134248. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2614","journal-title":"Clin Cancer Res"},{"key":"4809_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2016.16","volume":"5","author":"R Montler","year":"2016","unstructured":"Montler R, Bell RB, Thalhofer C, Leidner R, Feng Z, Fox BA, Cheng AC, Bui TG, Tucker C, Hoen H, Weinberg A (2016) OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer. Clin Transl Immunol 5:e70. https:\/\/doi.org\/10.1038\/cti.2016.16","journal-title":"Clin Transl Immunol"},{"key":"4809_CR10","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/hep.27188","volume":"60","author":"S Piconese","year":"2014","unstructured":"Piconese S, Timperi E, Pacella I, Schinzari V, Tripodo C, Rossi M, Guglielmo N, Mennini G, Grazi GL, Di Filippo S, Brozzetti S, Fazzi K, Antonelli G, Lozzi MA, Sanchez M, Barnaba V (2014) Human OX40 tunes the function of regulatory T cells in tumor and nontumor areas of hepatitis C virus-infected liver tissue. Hepatology 60:1494\u20131507. https:\/\/doi.org\/10.1002\/hep.27188","journal-title":"Hepatology"},{"key":"4809_CR11","doi-asserted-by":"publisher","first-page":"e1175800","DOI":"10.1080\/2162402X.2016.1175800","volume":"5","author":"E Timperi","year":"2016","unstructured":"Timperi E, Pacella I, Schinzari V, Focaccetti C, Sacco L, Farelli F, Caronna R, Del Bene G, Longo F, Ciardi A, Morelli S, Vestri AR, Chirletti P, Barnaba V, Piconese S (2016) Regulatory T cells with multiple suppressive and potentially pro-tumor activities accumulate in human colorectal cancer. Oncoimmunology 5:e1175800. https:\/\/doi.org\/10.1080\/2162402X.2016.1175800","journal-title":"Oncoimmunology"},{"key":"4809_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1399-0039.2006.00584.x","volume":"67","author":"F Xie","year":"2006","unstructured":"Xie F, Wang Q, Chen Y, Gu Y, Shi Q, Ge Y, Yu G, Wu H, Mao Y, Wang X, Zhou Y, Zhang X (2006) Characterization and application of two novel monoclonal antibodies against human OX40: costimulation of T cells and expression on tumor as well as normal gland tissues. Tissue Antigens 67:307\u2013317. https:\/\/doi.org\/10.1111\/j.1399-0039.2006.00584.x","journal-title":"Tissue Antigens"},{"key":"4809_CR13","doi-asserted-by":"publisher","first-page":"A420","DOI":"10.1136\/jitc-2020-SITC2020.0699","volume":"8","author":"Y Liu","year":"2020","unstructured":"Liu Y, Jiang B, Zhang T, Wang Z, Feng Y, Li H, Gong W, Wang X, Gao Y, Zhou X, Zhang B, Hong Y, Wang J, Wang Z, Hou H, Sun H, Song X, Li K, Liu X (2020) 699\u2005A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models. J Immunother Cancer 8:A420. https:\/\/doi.org\/10.1136\/jitc-2020-SITC2020.0699","journal-title":"J ImmunotherCancer"},{"key":"4809_CR14","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1007\/s11684-023-0996-8","volume":"17","author":"B Jiang","year":"2023","unstructured":"Jiang B, Zhang T, Deng M, Jin W, Hong Y, Chen X et al (2023) BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models. Front Med 17:1170\u20131185. https:\/\/doi.org\/10.1007\/s11684-023-0996-8","journal-title":"Front Med"},{"key":"4809_CR15","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1158\/1078-0432.CCR-20-1830","volume":"27","author":"M Gutierrez","year":"2021","unstructured":"Gutierrez M, Moreno V, Heinhuis KM, Olszanski AJ, Spreafico A, Ong M et al (2021) OX40 agonist BMS-986178 alone or in combination with nivolumab and\/or ipilimumab in patients with advanced solid tumors. Clin Cancer Res 27:460\u2013472. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1830","journal-title":"Clin Cancer Res"},{"key":"4809_CR16","doi-asserted-by":"publisher","first-page":"e005301","DOI":"10.1136\/jitc-2022-005301","volume":"11","author":"S Postel-Vinay","year":"2023","unstructured":"Postel-Vinay S, Lam VK, Ros W, Bauer TM, Hansen AR, Cho DC et al (2023) First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). J Immunother Cancer 11:e005301. https:\/\/doi.org\/10.1136\/jitc-2022-005301","journal-title":"J Immunother Cancer"},{"key":"4809_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/1078-0432.CCR-21-0845","volume":"28","author":"A Diab","year":"2022","unstructured":"Diab A, Hamid O, Thompson JA, Ros W, Eskens F, Doi T, Hu-Lieskovan S, Klempner SJ, Ganguly B, Fleener C, Wang X, Joh T, Liao K, Salek-Ardakani S, Taylor CT, Chou J, El-Khoueiry AB (2022) A phase I, open-label, dose-escalation study of the OX40 agonist ivuxolimab in patients with locally advanced or metastatic cancers. Clin Cancer Res 28:71\u201383. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0845","journal-title":"Clin Cancer Res"},{"key":"4809_CR18","doi-asserted-by":"publisher","first-page":"5358","DOI":"10.1158\/1078-0432.CCR-19-3070","volume":"26","author":"BS Glisson","year":"2020","unstructured":"Glisson BS, Leidner RS, Ferris RL, Powderly J, Rizvi NA, Keam B, Schneider R, Goel S, Ohr JP, Burton J, Zheng Y, Eck S, Gribbin M, Streicher K, Townsley DM, Patel SP (2020) Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors. Clin Cancer Res 26:5358\u20135367. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3070","journal-title":"Clin Cancer Res"},{"key":"4809_CR19","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1158\/1078-0432.CCR-21-4020","volume":"28","author":"TW Kim","year":"2022","unstructured":"Kim TW, Burris HA, de Miguel Luken MJ, Pishvaian MJ, Bang YJ, Gordon M et al (2022) First-in-human phase I study of the OX40 agonist MOXR0916 in patients with advanced solid tumors. Clin Cancer Res 28:3452\u20133463. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-4020","journal-title":"Clin Cancer Res"},{"key":"4809_CR20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1053\/j.gastro.2020.03.018","volume":"159","author":"Y Ma","year":"2020","unstructured":"Ma Y, Li J, Wang H, Chiu Y, Kingsley CV, Fry D, Delaney SN, Wei SC, Zhang J, Maitra A, Yee C (2020) Combination of PD-1 inhibitor and OX40 agonist induces tumor rejection and immune memory in mouse models of pancreatic cancer. Gastroenterology 159:306\u2013319e312. https:\/\/doi.org\/10.1053\/j.gastro.2020.03.018","journal-title":"Gastroenterology"},{"key":"4809_CR21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40265-020-01286-z","volume":"80","author":"A Lee","year":"2020","unstructured":"Lee A, Keam SJ (2020) Tislelizumab: first approval. Drugs 80:617\u2013624. https:\/\/doi.org\/10.1007\/s40265-020-01286-z","journal-title":"Drugs"},{"key":"4809_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ccell.2015.08.004","volume":"28","author":"R Dahan","year":"2015","unstructured":"Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV (2015) Fc\u03b3Rs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 axis. Cancer Cell 28:285\u2013295. https:\/\/doi.org\/10.1016\/j.ccell.2015.08.004","journal-title":"Cancer Cell"},{"key":"4809_CR23","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","volume":"67","author":"T Zhang","year":"2018","unstructured":"Zhang T, Song X, Xu L, Ma J, Zhang Y, Gong W et al (2018) The binding of an anti-PD-1 antibody to Fc\u03b3R\u0399 has a profound impact on its biological functions. Cancer Immunol Immunother 67:1079\u20131090. https:\/\/doi.org\/10.1007\/s00262-018-2160-x","journal-title":"Cancer Immunol Immunother"},{"key":"4809_CR24","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1200\/JCO.21.01926","volume":"40","author":"L Shen","year":"2022","unstructured":"Shen L, Kato K, Kim SB, Ajani JA, Zhao K, He Z et al (2022) Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study. J Clin Oncol 40:3065\u20133076. https:\/\/doi.org\/10.1200\/JCO.21.01926","journal-title":"J Clin Oncol"},{"key":"4809_CR25","doi-asserted-by":"publisher","first-page":"10472","DOI":"10.26355\/eurrev_202311_34324","volume":"27","author":"JW Shi","year":"2023","unstructured":"Shi JW, Zhou Y, Wu S (2023) Clinical efficacy and safety of adjuvant immunotherapy (tislelizumab) plus chemotherapy vs. adjuvant chemotherapy alone in lymph node-positive patients with gastric cancer after D2 radical resection: a prospective, 2-arm, phase II study. Eur Rev Med Pharmacol Sci 27:10472\u201310480. https:\/\/doi.org\/10.26355\/eurrev_202311_34324","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"4809_CR26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2217\/imt-2023-0130","volume":"16","author":"X Wang","year":"2024","unstructured":"Wang X, Pan H, Cui J, Chen X, Yoon WH, Carlino MS, Li X, Li H, Zhang J, Sun J, Guo J, Cui C (2024) SAFFRON-103: a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory\/resistant advanced melanoma. Immunotherapy 16:243\u2013256. https:\/\/doi.org\/10.2217\/imt-2023-0130","journal-title":"Immunotherapy"},{"key":"4809_CR27","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.acuroe.2023.12.006","volume":"48","author":"Z Wang","year":"2023","unstructured":"Wang Z, Bi H, Wang YD, Liu Q, Shao B, Li CQ, Fu C, Fu S, Shan GY, Chen A, Lv CC, Zeng Y (2023) Tislelizumab, a novel PD-1 monoclonal antibody in urothelial cancer: a real-world study. Actas Urol Esp (Engl Ed) 48:295\u2013303. https:\/\/doi.org\/10.1016\/j.acuroe.2023.12.006","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"4809_CR28","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","volume":"41","author":"Y Yang","year":"2023","unstructured":"Yang Y, Pan J, Wang H, Zhao Y, Qu S, Chen N et al (2023) Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309). Cancer Cell 41:1061\u20131072e1064. https:\/\/doi.org\/10.1016\/j.ccell.2023.04.014","journal-title":"Cancer Cell"},{"key":"4809_CR29","unstructured":"BeiGene (2022) China NMPA approves tislelizumab for patients with second-line esophageal squamous cell carcinoma. https:\/\/ir.beigene.com\/news\/china-nmpa-approves-tislelizumab-for-patients-with-second-line-esophageal-squamous-cell-carcinoma\/50b0ad83-47cf-46e7-a6fd-53ccc04058f2\/. Accessed 16 August 2024"},{"key":"4809_CR30","unstructured":"BeiGene (2023) BeiGene announces positive regulatory updates in Europe and the U.S. after recently regaining global rights for TEVIMBRA\u00ae. https:\/\/ir.beigene.com\/news\/beigene-announces-positive-regulatory-updates-in-europe-and-the-u-s-after-recently-regaining-global-rights\/5e4692d6-d726-4989-a659-49dc97d4d7ed\/. Accessed 16 August 2024"},{"key":"4809_CR31","unstructured":"Pelosci A (2024) FDA approves second-line tislelizumab monotherapy in esophageal cancer. https:\/\/www.cancernetwork.com\/view\/fda-approves-second-line-tislelizumab-monotherapy-in-esophageal-cancer. Accessed August 16, 2024"},{"key":"4809_CR32","unstructured":"Conroy R (2024) Tislelizumab earns European approval in non\u2013small cell lung cancer. https:\/\/www.cancernetwork.com\/view\/tislelizumab-earns-european-approval-in-non-small-cell-lung-cancer. Accessed 16 August 2024"},{"key":"4809_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cct.2017.04.006","volume":"58","author":"W Guo","year":"2017","unstructured":"Guo W, Wang SJ, Yang S, Lynn H, Ji Y (2017) A bayesian interval dose-finding design addressing Ockham\u2019s razor: mTPI-2. Contemp Clin Trials 58:23\u201333. https:\/\/doi.org\/10.1016\/j.cct.2017.04.006","journal-title":"Contemp Clin Trials"},{"key":"4809_CR34","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1177\/1740774510382799","volume":"7","author":"Y Ji","year":"2010","unstructured":"Ji Y, Liu P, Li Y, Bekele BN (2010) A modified toxicity probability interval method for dose-finding trials. Clin Trials 7:653\u2013663. https:\/\/doi.org\/10.1177\/1740774510382799","journal-title":"Clin Trials"},{"key":"4809_CR35","unstructured":"Devanaryan V (2016) Interpretation of immunogenicity results and evaluation of clinical associations. European Bioanalysis Forum (EBF) 9th Open Meeting, November 16\u201318, 2016; Barcelona, Spain"},{"key":"4809_CR36","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1161\/01.RES.83.4.463","volume":"83","author":"Y Seko","year":"1998","unstructured":"Seko Y, Takahashi N, Azuma M, Yagita H, Okumura K, Yazaki Y (1998) Expression of costimulatory molecule CD40 in murine heart with acute myocarditis and reduction of inflammation by treatment with anti-CD40L\/B7-1 monoclonal antibodies. Circ Res 83:463\u2013469. https:\/\/doi.org\/10.1161\/01.RES.83.4.463","journal-title":"Circ Res"},{"key":"4809_CR37","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jaut.2011.01.006","volume":"36","author":"G Fousteri","year":"2011","unstructured":"Fousteri G, Dave A, Morin B, Omid S, Croft M, von Herrath MG (2011) Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditis. J Autoimmun 36:210\u2013220. https:\/\/doi.org\/10.1016\/j.jaut.2011.01.006","journal-title":"J Autoimmun"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04809-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04809-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04809-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T14:33:00Z","timestamp":1759933980000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04809-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4809"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04809-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.D. has served in a consulting or advisory role for BeOne Medicines, Pierre Fabre, Bayer, GlaxoSmithKline, Merck KGaA, Boehringer Ingelheim, Roche\/Genentech, Daiichi Sankyo Europe GmbH, and Amgen; and J.D.\u2019s institution has received research funding from Roche, GlaxoSmithKline, Novartis, Bionomics, BeOne Medicines, Lilly, Bristol Myers Squibb, and AstraZeneca\/MedImmune. S.D. has received travel, accommodations, or expenses from Roche. B.G. has served in a consulting or advisory role for MSD, BeOne Medicines, and IMPAC Medical Systems. K.Y. has nothing to disclose. J.O. has stock and other ownership interests from Carpe Vitae Pharmaceuticals, RepLica Pharmaceuticals, and DGC Diagnostics; has received honoraria from Merck Sharp & Dohme, Bristol Myers Squibb, Roche, Boehringer Ingelheim, AstraZeneca, Pfizer\/EMD Serono, Novartis, Janssen-Cilag, Yuan, Merck Group, TriStar Technology Group, Takeda Pharmaceuticals, Amgen, BeOne Medicines, and Ipsen; has served in a consulting or advisory role for Merck Sharp & Dohme, Boehringer Ingelheim, Roche\/Genentech, Janssen-Cilag, Pfizer, AstraZeneca\/MedImmune, Bristol Myers Squibb, Novartis, Yuhan, Sanofi, Amgen, BeOne Medicines, and Ipsen; has had speakers\u2019 bureau roles for Merck Sharp & Dohme, Boehringer Ingelheim, Bristol Myers Squibb, Roche, Janssen-Cilag, Pfizer, and Merck Group; and is named on four active patents (two published and two provisional) for his institution. M.S. has nothing to disclose. T.L. has served as a principal investigator for BeOne Medicines. T.M. has served in a consulting or advisory role for Novartis, GlaxoSmithKline, Bristol Myers Squibb, Eisai, Regeneron, Sanofi, and MSD; and has received travel expenses from Bristol Myers Squibb. T.M.\u2019s institution has received research funding from Bristol Myers Squibb, Incyte, BeOne Medicines, AstraZeneca\/MedImmune, Regeneron, Bayer, Merck Serono, and Roche\/Genentech. X.Y. has nothing to disclose. M.V. has received honoraria from MSD; has participated in a consulting or advisory role for AstraZeneca and MSD; has received institutional funding from AstraZeneca\/MedImmune, AstraZeneca, MSA, Alpine Immune Sciences, ViroCure, Hinova Pharmaceuticals, Atridia, Antengene, BeOne Medicines, and Hengrui Pharmaceutical. D.Davar has received honoraria from Castle Biosciences; has held a consulting or advisory role for ACM Bio, Ascendis Pharma, Clinical Care Options, Gerson Lehrman Group, Merck, Medical Learning Group, and Xilio Therapeutics; has received research funding from Arcus, CellSight Technologies, Immunocore, Merck, Regeneron Pharmaceuticals, and Tesaro\/GlaxoSmithKline; has participated in a speakers\u2019 bureau for Castle Biosciences; and held US Patent 63\/124,231, \u201cCompositions and Methods for Treating Cancer\u201d, 11 December 2020, and US Patent 63\/208,719, \u201cCompositions and Methods For Responsiveness to Immune Checkpoint Inhibitors (ICI), Increasing Effectiveness of ICI and Treating Cancer\u201d, 9 June 2021. M.M. has nothing to disclose. S.L. is an employee of BeOne Medicines and has stock or ownership interest in BeOne Medicines. T.R. is an employee of BeOne Medicines and has stock or other ownership interests in BeOne Medicines. X.Q. is an employee of BeOne Medicines. H.G. was employed in the past by Theravance Biopharma, and is currently employed by BeOne Medicines, and has stock or other ownership interests in both companies. X.C. is an employee of BeOne Medicines, has stock or ownership interest in BeOne Medicines, and has received research funding from and has patents with BeOne Medicines. Y.D. is an employee of BeOne Medicines, has stock or ownership interest in BeOne Medicines, and has patents with BeOne Medicines. D.Day has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol and its amendments were approved by the appropriate local or national ethics body or institutional review boards for each participating center. The trial was conducted according to the principles of the Declaration of Helsinki and the International Council for Harmonisation Good Clinical Practice guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patients provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"99"}}